美国 · SEC FORM 4
Surrozen, Inc./DE
SRZN · Nasdaq · CIK 0001824893 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
11 同一窗口内观察到的 Form 4 交易行
4 sales · 7 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-03-24 · TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC · $1.3M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Williams Charles OChief Operating Officer
○▼○
Parker Craig CChief Executive Officer
○▼○
Li YangExec. Vice President, Research
○▼○
Maleki Andrew PedrumChief Financial Officer
○
TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC; Yu Chen-MingTenPercentOwner
▼
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-24 · TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC.
近期 Form 4 活动
53买入
6卖出
12其他 Form 4 交易行
27SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出4 sale line(s) · 仅供背景
其他7 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,189,760
- 上期报告
- 2,195,505
- 日均成交量
- 1,450,761
- 回补天数
- 1.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-24 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 53,329 | USD 24.69 | USD 1,316,693 | SEC 申报 ↗ |
| 2026-03-23 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 15,223 | USD 24.90 | USD 379,053 | SEC 申报 ↗ |
| 2026-03-16 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 595 | USD 24.99 | USD 14,869 | SEC 申报 ↗ |
| 2026-03-13 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 35,433 | USD 24.88 | USD 881,573 | SEC 申报 ↗ |
| 2026-03-12 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 6,187 | USD 24.99 | USD 154,613 | SEC 申报 ↗ |
| 2026-02-12 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 1,093 | USD 23.86 | USD 26,079 | SEC 申报 ↗ |
| 2026-02-11 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 17,763 | USD 23.58 | USD 418,852 | SEC 申报 ↗ |
| 2026-02-03 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 4,355 | USD 21.94 | USD 95,549 | SEC 申报 ↗ |
| 2026-02-02 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 731 | USD 21.38 | USD 15,629 | SEC 申报 ↗ |
| 2026-01-30 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 4,271 | USD 21.39 | USD 91,357 | SEC 申报 ↗ |
| 2026-01-20 | Kutzkey Tim | 买入 (P) | Common Stock | 18,052 | USD 19.60 | USD 353,819 | SEC 申报 ↗ |
| 2026-01-20 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 18,052 | USD 19.60 | USD 353,819 | SEC 申报 ↗ |
| 2026-01-16 | Kutzkey Tim | 买入 (P) | Common Stock | 2,562 | USD 20.00 | USD 51,240 | SEC 申报 ↗ |
| 2026-01-16 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 2,562 | USD 20.00 | USD 51,240 | SEC 申报 ↗ |
| 2026-01-15 | Kutzkey Tim | 买入 (P) | Common Stock | 11,893 | USD 19.89 | USD 236,552 | SEC 申报 ↗ |
Form 4 申报证据
71 transaction lines in the latest 365-day window; 170 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC; Yu Chen-Ming | 卖出 (S) | Common Stock | 162,500 | USD 21.25 | USD 3,453,125 | SEC 申报 ↗ |
| 2026-06-15 | Williams Charles O | 奖励／授予 (A) | Common Stock | 1,666 | USD 8.11 | USD 13,511 | SEC 申报 ↗ |
| 2026-06-15 | Parker Craig C | 奖励／授予 (A) | Common Stock | 1,622 | USD 8.11 | USD 13,154 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC; Yu Chen-Ming | 卖出 (S) | Common Stock | 162,500 | USD 21.25 | USD 3,453,125 | SEC 申报 ↗ |
| 2026-06-15 | Williams Charles O | 奖励／授予 (A) | Common Stock | 1,666 | USD 8.11 | USD 13,511 | SEC 申报 ↗ |
| 2026-06-15 | Parker Craig C | 奖励／授予 (A) | Common Stock | 1,622 | USD 8.11 | USD 13,154 | SEC 申报 ↗ |
| 2026-06-15 | Maleki Andrew Pedrum | 奖励／授予 (A) | Common Stock | 607 | USD 19.01 | USD 11,539 | SEC 申报 ↗ |
| 2026-06-15 | Li Yang | 奖励／授予 (A) | Common Stock | 1,666 | USD 8.11 | USD 13,511 | SEC 申报 ↗ |
| 2026-05-04 | Williams Charles O | 卖出 (S) | Common Stock | 2,036 | USD 33.33 | USD 67,860 | SEC 申报 ↗ |
| 2026-05-04 | Parker Craig C | 卖出 (S) | Common Stock | 4,524 | USD 33.33 | USD 150,785 | SEC 申报 ↗ |
| 2026-05-04 | Li Yang | 卖出 (S) | Common Stock | 1,584 | USD 33.33 | USD 52,795 | SEC 申报 ↗ |
| 2026-05-01 | Williams Charles O | 期权行权／转换 (M) | Common Stock | 5,625 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Parker Craig C | 期权行权／转换 (M) | Common Stock | 12,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Li Yang | 期权行权／转换 (M) | Common Stock | 4,375 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-24 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 53,329 | USD 24.69 | USD 1,316,693 | SEC 申报 ↗ |
| 2026-03-23 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 15,223 | USD 24.90 | USD 379,053 | SEC 申报 ↗ |
| 2026-03-16 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 595 | USD 24.99 | USD 14,869 | SEC 申报 ↗ |
| 2026-03-13 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 35,433 | USD 24.88 | USD 881,573 | SEC 申报 ↗ |
| 2026-03-12 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 6,187 | USD 24.99 | USD 154,613 | SEC 申报 ↗ |
| 2026-02-12 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 1,093 | USD 23.86 | USD 26,079 | SEC 申报 ↗ |
| 2026-02-11 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 17,763 | USD 23.58 | USD 418,852 | SEC 申报 ↗ |
| 2026-02-03 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 4,355 | USD 21.94 | USD 95,549 | SEC 申报 ↗ |
| 2026-02-02 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 731 | USD 21.38 | USD 15,629 | SEC 申报 ↗ |
| 2026-01-30 | TCG Crossover Fund II, L.P.; TCG Crossover Fund III, L.P.; TCG Crossover GP II, LLC; TCG Crossover GP III, LLC | 买入 (P) | Common Stock | 4,271 | USD 21.39 | USD 91,357 | SEC 申报 ↗ |
| 2026-01-20 | Kutzkey Tim | 买入 (P) | Common Stock | 18,052 | USD 19.60 | USD 353,819 | SEC 申报 ↗ |
| 2026-01-20 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 18,052 | USD 19.60 | USD 353,819 | SEC 申报 ↗ |
| 2026-01-16 | Kutzkey Tim | 买入 (P) | Common Stock | 2,562 | USD 20.00 | USD 51,240 | SEC 申报 ↗ |
| 2026-01-16 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 2,562 | USD 20.00 | USD 51,240 | SEC 申报 ↗ |
| 2026-01-15 | Kutzkey Tim | 买入 (P) | Common Stock | 11,893 | USD 19.89 | USD 236,552 | SEC 申报 ↗ |
| 2026-01-15 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 11,893 | USD 19.89 | USD 236,552 | SEC 申报 ↗ |
| 2026-01-14 | Kutzkey Tim | 买入 (P) | Common Stock | 5,523 | USD 19.99 | USD 110,405 | SEC 申报 ↗ |
| 2026-01-14 | COLUMN GROUP III GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Svennilson Peter; TCG Opportunity III GP, LLC | 买入 (P) | Common Stock | 5,523 | USD 19.99 | USD 110,405 | SEC 申报 ↗ |
| 2026-01-13 | Kutzkey Tim | 买入 (P) | Common Stock | 12,470 | USD 19.80 | USD 246,906 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SRZN |
| CIK | 0001824893 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 170 transaction lines from 2020-09-04 to 2026-07-22 77 P purchase lines · 16 S sale lines · 77 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.